MANTLE CELL LYMPHOMA

This study tests a new drug called AZD4512, alone or with other cancer medicines, in adults with relapsed or refractory B-cell Non-Hodgkin lymphoma (a type of blood cancer). The goal is to find safe doses and check if the drug shrinks tumors. About 91 participants will take part …

This early-stage trial is testing a new drug called MK-1045 (CN201) in about 100 people whose B-cell non-Hodgkin lymphoma has returned or stopped responding to treatment. MK-1045 is an immunotherapy designed to help the immune system fight the cancer. The main goals are to check …

This Phase 2 trial is testing a stem cell transplant from a donor for people with various blood cancers and bone marrow disorders. The transplant uses strong chemotherapy or radiation to wipe out the diseased marrow, then replaces it with healthy donor cells. A new combination of…

This Phase 2 trial is testing a drug called glofitamab in 41 people with mantle cell lymphoma whose cancer did not respond or came back after CAR T-cell therapy. The goal is to see if glofitamab can shrink or control the cancer. Researchers will measure how many patients achieve …

This study tests whether adding sonrotoclax to the standard drug zanubrutinib helps adults with mantle cell lymphoma that has returned or stopped responding to prior therapy. About 300 participants will receive either the combination or a placebo plus zanubrutinib. The main goal …

This early-stage trial tests IM-1021, an antibody-drug conjugate designed to deliver a cancer-killing drug directly to tumor cells. It enrolls 117 adults with advanced solid tumors or B-cell lymphomas that have not responded to standard treatments. The main goals are to check saf…

This early-phase trial is testing a treatment where a patient's own immune cells are modified in a lab to better recognize and attack cancer cells. It is for people with certain types of Non-Hodgkin lymphoma that have come back or not responded to standard treatments. The main go…

This study tests a combination of five drugs (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, called ViPOR) in adults with B-cell lymphoma that has come back or not responded to prior treatment. The main goal is to check the safety of this drug mix. Up to 155 p…

This study tests a new oral drug, BGB-16673, designed to destroy a protein called BTK that helps certain blood cancers grow. The trial includes about 645 people with various B-cell cancers (like lymphoma and leukemia) that have come back or not responded to prior treatments. The …

This study tests a new drug called acalabrutinib combined with standard chemotherapy (R-CHOP) in people with untreated mantle cell lymphoma who cannot have a stem cell transplant. The goal is to see how well the combination shrinks tumors and how safe it is. Participants will con…

This study tests a new drug called AZD0486, alone or with other cancer drugs, in people with B-cell blood cancers like certain lymphomas and leukemias. The goal is to see if it is safe and helps shrink or control the cancer. About 408 adults will take part in this early-phase tri…

This phase 2 study tests an oral drug called nemtabrutinib in about 490 people with blood cancers like chronic lymphocytic leukemia, non-Hodgkin lymphoma, and Waldenstrom's macroglobulinemia. The goal is to see if the drug can shrink tumors and control the cancer, while also chec…

This study tests new ways to give the drug sonrotoclax to adults with chronic lymphocytic leukemia or mantle cell lymphoma. The goal is to find a dosing schedule that lowers the risk of tumor lysis syndrome, a serious side effect. About 258 participants will be enrolled to check …

This study tests whether giving donor white blood cells (lymphocytes) soon after a stem cell transplant can lower the chance of cancer returning in people with high-risk blood cancers like leukemia or lymphoma. Participants receive chemotherapy, a stem cell transplant, and then a…

This study offers continued access to the drug ibrutinib for up to 700 people with certain blood cancers (like CLL, lymphoma, and Waldenstrom macroglobulinemia) who are already taking it and benefiting. Researchers will track side effects and how the disease changes over time. Th…

This early study is testing an injection called IASO208 in 12 adults with certain types of blood cancer that have returned or not improved with standard treatments. The main goal is to see if the treatment is safe and to find the right dose. Researchers will also look at how well…

This study looks at whether older adults with mantle cell lymphoma (MCL) who achieve remission can safely stop taking zanubrutinib and restart it only if the cancer returns, instead of taking it every day forever. About 421 people will be randomly assigned to either continuous or…

This early study tests a new treatment called KSVCBD for people with a type of blood cancer called B-cell non-Hodgkin's lymphoma that has come back or not responded to other treatments. KSVCBD is a special therapy that works inside the body to help immune cells attack cancer cell…

This study tests an experimental drug called epcoritamab given together with other anti-cancer medicines in adults with Non-Hodgkin lymphoma (NHL), a type of blood cancer. About 496 participants will receive different combinations depending on their lymphoma subtype and treatment…

This study tests a stem cell transplant from half-matched (haploidentical) donors for people with various blood cancers. Before the transplant, patients receive chemotherapy and low-dose radiation to prepare their body. The goal is to replace diseased bone marrow with healthy don…

This phase 3 trial compares two drug combinations given after a stem cell transplant to prevent graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. The study will enroll 572 adults with blood cancers like leukemia or myelodysplasi…

This early-phase study tests a new treatment called JV-213 for adults with B-cell lymphoma that has come back or not responded to other treatments. JV-213 uses the patient's own immune cells, modified to attack cancer cells. The main goal is to find the safest dose and monitor si…

This study tests whether adding two oral medications (sonrotoclax and zanubrutinib) to standard CAR-T cell therapy can improve treatment results for people with mantle cell lymphoma that has come back or not responded to prior treatment. About 40 adults who are already eligible f…

This study is testing a combination of three drugs (obinutuzumab, zanubrutinib, and lenalidomide) as a first treatment for people with mantle cell lymphoma who have not had any prior therapy. About 37 adults aged 18 to 80 will receive the drugs, and those at higher risk may also …

This Phase 2 trial is testing a combination of three drugs—zanubrutinib, obinutuzumab, and venetoclax—in people with previously untreated chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or mantle cell lymphoma (MCL). The goal is to see if the combo can make …

This early-phase trial is testing whether adding a patient's own blood stem cells to standard CAR T-cell therapy is safe and doable for people with relapsed or refractory blood cancers like lymphoma, leukemia, and myeloma. Twenty participants will receive their own stem cells 10 …

This study tests whether combining two oral drugs, pirtobrutinib and venetoclax, can control mantle cell lymphoma (MCL) in patients whose cancer has come back or hasn't responded to prior treatments. About 30 adults with confirmed MCL will take these pills to see how many achieve…

This study tests an experimental drug called MDX2003 in 180 adults with B-cell lymphomas (like diffuse large B-cell lymphoma or follicular lymphoma) that have returned or stopped responding to at least two prior treatments. The main goals are to find the safest dose and check if …

This early-stage trial is testing a new oral drug called JBZ-001 in 25 adults with advanced solid tumors or certain blood cancers (like lymphoma) that have not responded to standard treatments. The drug works by blocking a protein cancer cells need to grow. The main goals are to …

This Phase 2 trial is testing whether a combination of two drugs, pirtobrutinib and rituximab, can help people with untreated low or intermediate risk mantle cell lymphoma achieve long-term remission without chemotherapy. The study will enroll 50 adults who have not received prio…

This study tests a faster, hospital-based dose increase of the drug sonrotoclax for people with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or mantle cell lymphoma (MCL) that is new, has returned, or hasn't responded to treatment. Participants first rece…

This study is testing whether a combination of three drugs—venetoclax, lenalidomide, and rituximab—is safe and effective for people with untreated mantle cell lymphoma, a rare blood cancer. About 28 adults will take these pills and infusions over several months. The goal is to fi…

This early-phase study tests a new treatment called CT1182 for people with B-cell non-Hodgkin lymphoma that has come back or not responded to standard therapy. About 24 participants will receive the treatment to see if it is safe and how well it works. The goal is to find the bes…

This phase 2 trial tests whether alternating two chemotherapy regimens (RB and RBAC) works better than the standard RB regimen alone for elderly patients newly diagnosed with mantle cell lymphoma who are not eligible for a stem cell transplant. About 90 participants will be rando…

This phase 2 trial tests whether combining glofitamab (an antibody that helps immune cells attack cancer) with pirtobrutinib (a pill that blocks cancer growth signals) is safe and effective for adults with mantle cell lymphoma that has come back or not responded to treatment. Abo…

This study tests a new drug called BGB-16673 for people in China with certain blood cancers (B-cell malignancies) that have come back or not responded to treatment. The drug works by breaking down a protein that helps cancer cells grow. The trial has two parts: first, finding the…

This study tests a new treatment called TranspoCART19 for people with B-cell lymphoma that has come back or not responded to standard therapy. The treatment uses a patient's own immune cells, which are genetically modified to better recognize and attack cancer cells. The trial wi…

This study is testing whether a drug called polatuzumab vedotin can safely help control lymphoma after a stem cell transplant. About 20 people with B-cell or Hodgkin lymphoma who have had a relapse or not responded to prior treatment will receive the drug if their disease is stab…

This early-phase study tests a new treatment called SynKIR-310 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, modified to target and attack cancer cells. The main go…

This study tests a personalized CAR T-cell therapy for people with B-cell lymphoma that has come back or not responded to treatment. Patients' own immune cells are collected, modified to target cancer cells, and infused back. The trial has two phases: first to find the safest dos…

This expanded access study provides brexacabtagene autoleucel (Tecartus) to patients with mantle cell lymphoma or acute lymphoblastic leukemia whose commercially manufactured batch did not meet release specifications but still meets internal clinical trial criteria. Eligible pati…

This early-stage trial tests a new treatment called CLIC-2201 for people with B-cell cancers (like certain leukemias and lymphomas) that have come back or not responded to standard care. The treatment involves collecting a patient's own immune cells, modifying them to target a pr…

This early-stage trial tests a single-dose gene therapy called VNX-101 for people with certain blood cancers (like leukemia or lymphoma) that have returned or not responded to standard treatment. The therapy delivers instructions to the body to make a protein that helps immune ce…

This phase 2 trial tests whether adding the drug pirtobrutinib to a CAR-T cell therapy (brexucabtagene autoleucel) works better than CAR-T alone for people with mantle cell lymphoma that has come back or stopped responding to treatment. About 60 adults will be randomly assigned t…

This study tests a personalized cell therapy called Talikabtagene Autoleucel for people with B-cell leukemia or lymphoma that has returned or not responded to standard treatment. The therapy uses a patient's own immune cells, which are modified in a lab to recognize and attack ca…

This early-phase trial is testing a new version of CAR T-cell therapy that has been modified to improve its energy use, potentially making the cells more effective. It is for adults with certain types of B-cell lymphoma or chronic lymphocytic leukemia that have come back or not r…

This early-phase study tests a new type of immune cell therapy (CAR T cells) that targets two proteins, CD79b and CD19, on lymphoma cells. It is for people with non-Hodgkin lymphoma whose cancer has returned or stopped responding to standard treatments. The main goals are to chec…

This study tests a combination of two drugs, nemtabrutinib and rituximab, in people with untreated mantle cell lymphoma. The goal is to see if this combo can shrink or eliminate cancer more effectively. About 27 adults will take part, receiving the drugs as pills and infusions. T…

This early-phase study is testing a new biologic drug called PIC1 injection in 18 adults with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The main goal is to check safety and find the right dose, while also seeing if it can shrink tumors. It is t…

This study tests an experimental drug called CHO-H01, alone or with lenalidomide, in people with non-Hodgkin lymphoma that has returned or not responded to prior treatments. The trial has two parts: first, finding a safe dose of CHO-H01 alone; second, testing the combination in l…

This study at Mayo Clinic looks at how often high blood pressure happens in patients with certain blood cancers (like CLL or lymphoma) who are taking a type of targeted drug called a BTK inhibitor. It will track 100 patients over a year to see if managing blood pressure well can …

This early-phase trial is testing whether giving special immune cells (CMV-specific CD19-CAR T cells) along with a vaccine (CMV-MVA triplex) after a stem cell transplant can safely help prevent B-cell non-Hodgkin lymphoma from returning. About 15 people with intermediate or high-…

This early-phase study tests a new treatment for adults with certain types of blood cancer (like lymphoma) that have come back or not responded to standard therapies. The treatment combines a targeted drug (pirtobrutinib) with specially engineered immune cells (CAR T-cells) desig…

This phase 2 trial is testing a five-drug combination for people with untreated mantle cell lymphoma. The treatment includes standard chemotherapy plus newer targeted drugs. After initial therapy, some participants will receive an additional drug (sonrotoclax) to see if it helps …

This study is testing a combination of three drugs (glofitamab, venetoclax, and lenalidomide) in people newly diagnosed with a fast-growing type of mantle cell lymphoma. The goal is to see if this mix is safe and works better than current treatments. About 50 adults aged 18 to 80…

This early-phase study is testing an experimental oral drug called LP-168 in about 60 people with several types of B-cell blood cancers that have come back or not responded to prior treatments. The main goals are to find the safest dose and to see how the drug behaves in the body…

This early-phase trial tests a new drug, SGR-1505, in about 98 adults with various B-cell blood cancers (like lymphoma or leukemia) that have not responded to other treatments. The main goals are to find the safest dose and understand side effects. Participants will receive the d…

This phase 2 trial is testing a combination of two drugs, acalabrutinib and obinutuzumab, in people with untreated follicular lymphoma or other slow-growing non-Hodgkin lymphomas. The goal is to see if this drug pair can shrink tumors and control the disease. About 49 participant…

This study tests whether a new type of radiation machine that uses MRI to guide treatment is safe and practical for people with gastric, breast, or other cancers. About 70 adults will receive radiation guided by real-time MRI, sometimes with chemotherapy. The goal is to see if th…

This early-phase study tests a new approach for patients with B-cell lymphoma that has not responded to standard treatments. A specially designed virus is injected to deliver instructions that turn some of the patient's own immune cells into cancer-killing cells directly inside t…

This Phase 3 trial tests a new drug called rocbrutinib against other targeted therapies for mantle cell lymphoma, a type of blood cancer. About 394 adults whose cancer has returned or not responded to previous treatment will be randomly assigned to receive rocbrutinib or another …

This early-phase study is testing a new drug called YK012 in 48 adults with relapsed or refractory B-cell non-Hodgkin lymphoma. YK012 is a bispecific antibody designed to help the body's immune T cells recognize and kill cancer B cells. The main goals are to check the drug's safe…

This study tests a new treatment using immune cells (NK cells) from donated cord blood that are engineered to target a protein called CD5 found on certain cancer cells. The treatment is given after chemotherapy to prepare the body, and the goal is to see if it is safe and effecti…

This study tests a combination of three drugs—glofitamab, ibrutinib, and obinutuzumab—in people with mantle cell lymphoma who are either 65 or older, or between 18 and 64 with high-risk features. The goal is to see if the combo is safe and can shrink or eliminate tumors. Particip…

This early-phase trial is testing a new drug called NB02 (posseltinib) in 9 adults with certain types of Non-Hodgkin lymphoma (follicular, mantle cell, or marginal zone) that have returned or not responded to at least two prior treatments. The main goals are to find a safe dose a…

This study tests a combination of three drugs—acalabrutinib, venetoclax, and obinutuzumab—for people with mantle cell lymphoma that has come back or hasn't been treated yet. The goal is to find the best dose and see how well it works at shrinking tumors. About 72 participants wil…

This study tests a new treatment for people with certain types of lymphoma or leukemia that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The main goal is t…

This study tests a new treatment called SHB-04-CD22, which uses a patient's own immune cells (T-cells) engineered to find and attack cancer cells that have a protein called CD22. It is for children and adults (ages 1-80) with B-cell cancers that have come back or not responded to…

This study tests a new type of CAR-T cell therapy that uses mRNA to target two proteins (CD19 and CD20) on cancer cells. It is for people with B-cell lymphoma or leukemia that has come back or not responded to treatment. The goal is to see if it is safe and effective, with up to …

This study tests whether a combination of three drugs—acalabrutinib, obinutuzumab, and glofitamab—can safely treat mantle cell lymphoma that has come back or not responded to prior therapy. The drugs work by blocking cancer growth signals and helping the immune system attack canc…

This study tests whether adding two antibody drugs (mosunetuzumab and polatuzumab) after standard CAR-T cell therapy can improve tumor shrinkage in people with aggressive non-Hodgkin lymphoma that has relapsed or not responded to prior treatments. About 22 adults will receive the…

This early-stage trial tests a new drug called ONM-501, which is injected directly into tumors, either alone or with the immunotherapy cemiplimab (Libtayo). The study includes 168 adults with advanced solid tumors or lymphomas that have not responded to standard treatments. The m…

This early-stage trial tests an oral drug called AS-1763 in about 120 adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or other B-cell non-Hodgkin lymphomas who have already tried at least two other treatments. The study aims to find the safest dose and check…

This study tests whether low-intensity mechanical stimulation (LIMS) vibration therapy can help blood cancer patients who are about to receive a stem cell transplant or cell therapy. The vibration board sends gentle waves through the bones, which may stimulate bone growth, improv…

This phase II trial tests the drug pemigatinib (Pemazyre) in 27 adults with relapsed or refractory B-cell non-Hodgkin lymphomas, including mantle cell and marginal zone lymphoma. Participants take one pill daily in 28-day cycles. The main goal is to see if the drug can shrink tum…

This early-stage trial tests a new therapy made from cord blood immune cells (CAR NK cells) designed to target and kill B-cell lymphoma cells. It is for patients whose cancer has not responded to or has returned after standard treatments. The study will check safety and how well …

This early-stage study is testing a new immune cell therapy called CT1190B CAR-T in 27 adults with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The therapy involves modifying a patient's own immune cells to better recognize and attack cancer cells…

This study tests a new treatment called CTX112 for people with B-cell cancers (like lymphoma or leukemia) that have not responded to standard therapy or have returned. CTX112 uses CRISPR gene editing to modify immune cells from a healthy donor, making them target and kill cancer …

This study is testing a combination of two drugs, zanubrutinib and tafasitamab, in people with mantle cell lymphoma, a rare blood cancer. The first part of the trial will find the best dose of zanubrutinib when used with tafasitamab. The second part will see how well the combinat…

This early-stage trial tests a new drug called IKS03 in people with advanced B-cell non-Hodgkin lymphoma that has not responded to other treatments. The drug works like a guided missile, targeting a protein (CD19) on cancer cells to deliver a toxic payload. The study aims to find…

This Phase 2 trial tests a combination of the drug linperlisib plus three older drugs (cyclophosphamide, prednisone, and thalidomide) in 180 adults with non-Hodgkin lymphoma that has returned or not responded to treatment. The goal is to see how many patients achieve a complete o…

This early-stage trial is testing an experimental drug called LP-168, taken as a pill, in adults with B-cell lymphoma that has come back or not responded to standard treatments. The study aims to find the safest dose and check for side effects in about 200 participants. It is too…

This early-stage study tests an experimental drug called ICP-248, taken as a pill, for people with certain blood cancers (like leukemia or lymphoma). The drug is given alone or with another drug, orelabrutinib. The main goals are to check safety, find the right dose, and see if i…

This early-phase trial is testing a new treatment called OriV508 for people with multiple myeloma or non-Hodgkin lymphoma that has come back or stopped responding to other treatments. OriV508 is a type of immunotherapy that uses a virus to deliver instructions to the body to make…

This study tests a special PET/CT scan that uses radioactive tracers to find cancers that have a protein called CD70 on their surface. The cancers being studied include kidney cancer, lymphoma, and nasopharyngeal cancer. About 300 adults will receive an injection of the tracer an…

This study compares giving cancer treatment at home versus in a clinic for 27 adults with various cancers in the Florida Panhandle. The goal is to see if home treatment is preferred and improves satisfaction, while also checking safety. Participants will receive their usual cance…

This study watches people with blood cancers like CLL who take BTK inhibitors or venetoclax to see how these drugs affect heart rhythm. Researchers will use EKGs, stress tests, and heart monitors to track abnormal rhythms and sudden death risk. The goal is to better understand an…

This study looks at how the immune system of people with lymphoma responds to flu and COVID vaccines. Researchers will measure antibody levels and immune cells over time in 200 participants with different types of lymphoma. The goal is to understand how lymphoma and its treatment…

This study looks at how well vaccines for flu, COVID-19, shingles, hepatitis B, and pneumonia work in people with certain blood cancers like chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphomas. Researchers will measure immune responses through blood samples before and af…

This study follows 100 people taking newer BTK inhibitor drugs (acalabrutinib or zanubrutinib) for blood cancers like leukemia or lymphoma. Researchers want to see how often these drugs cause high blood pressure or heart rhythm problems, and find early warning signs. Participants…

This study follows 500 people who received CAR-T cells in earlier trials for blood cancers like lymphoma and multiple myeloma. Researchers will check for new cancers and track long-term safety and effectiveness over 15 years. No new treatment is given; it is purely an observation…

This study is testing whether an artificial intelligence (AI) tool can help match cancer patients with the right clinical trials. Researchers will enroll up to 50,000 people with various cancers to see if the AI improves trial enrollment rates and patient outcomes. The goal is to…

This study looks at whether CAR-T cell therapy reduces the body's ability to fight off diseases like measles and mumps that were previously prevented by vaccines. Researchers will measure antibody levels in 45 adults with multiple myeloma or non-Hodgkin lymphoma before and after …